Company intelligence / Profile preview
Ectin Research AB
Mölndal, Västra Götaland, Swedenectinresearch.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lead drug candidate MFA‑370 was in Phase I/II clinical trials for metastatic urothelial bladder cancer. No published results or further updates available prior to the company's decision to liquidate.
- The approach involved a combination therapy aiming to eliminate tumors.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (combination therapy involving two pharmaceuticals)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed
Beyond the preview
Go deeper on Ectin Research AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ectin Research AB.